Text
Link
Rel
Target
who is the patient?index2.php?page=8
when to suspect hitindex2.php?page=9
when does hit occur?index2.php?page=7
whats newindex2.php?page=69
what is hit?index2.php?page=4
what causes hit?index2.php?page=6
what are the complications?index2.php?page=5
use in dialysisindex4.php?page=75
ukindex2.php?page=150
treatment optionsindex2.php?page=33
the netherlandsindex2.php?page=16
the icu patientindex2.php?page=15
terms of useindex2.php?page=54
swedenindex2.php?page=17
spainindex2.php?page=16
site mapindex2.php?page=53
safety profileindex4.php?page=28
referencesindex4.php?page=78
preparationindex4.php?page=38
patient benefitsindex4.php?page=37
orderingindex4.php?page=39
norwayindex2.php?page=17
mitsubishi tanabe pharma corporationhttp://www.mitsubishi-pharma.eu/popup_corp.html
managing the hit patientindex2.php?page=14
laboratory testing for hitindex2.php?page=13
key featuresindex4.php?page=25
italyindex2.php?page=17
introductionindex2.php?page=24
icelandindex2.php?page=17
how does it work?index4.php?page=26
hit case study filmindex4.php?page=143
germanyindex4.php?page=77
germanunder_construction.php
further informationindex2.php?page=71
franceindex2.php?page=16
finlandindex2.php?page=17
faqsindex4.php?page=41
external sitesindex2.php?page=52
europeindex2.php?page=42
estimating the probabilityindex2.php?page=10
englishindex.php
dosage guidelinesindex4.php?page=29
dosage calculatorindex4.php?page=30
differentiationindex4.php?page=32
designed and developed by design by lovehttp://www.designbylove.co.uk_blank
denmarkindex2.php?page=17
clinical efficacyindex4.php?page=27
click hereindex4.php?page=143
bulletinsindex2.php?page=70
austriaindex4.php?page=77
ask the expertindex2.php?page=34
argatrobanindex4.php?page=74
after cardiac surgeryindex2.php?page=12
4tsindex2.php?page=11